Darwin Lewis Purchases 3,955 Shares of Lifevantage (NASDAQ:LFVN) Stock

Lifevantage Corporation (NASDAQ:LFVN) Director Darwin Lewis purchased 3,955 shares of the business’s stock in a transaction that occurred on Monday, February 9th. The shares were purchased at an average cost of $5.22 per share, with a total value of $20,645.10. Following the completion of the acquisition, the director directly owned 135,508 shares in the company, valued at $707,351.76. The trade was a 3.01% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Darwin Lewis also recently made the following trade(s):

• On Monday, December 15th, Darwin Lewis acquired 805 shares of Lifevantage stock. The shares were purchased at an average cost of $6.54 per share, for a total transaction of $5,264.70.

Lifevantage Trading Down 3.3%

NASDAQ:LFVN opened at $4.92 on Friday. The stock has a market capitalization of $62.93 million, a P/E ratio of 8.20 and a beta of 0.33. Lifevantage Corporation has a 1 year low of $3.90 and a 1 year high of $19.36. The firm has a 50 day moving average of $6.01 and a 200-day moving average of $8.64.

Lifevantage (NASDAQ:LFVN) last released its quarterly earnings results on Wednesday, February 4th. The company reported $0.15 EPS for the quarter, missing analysts’ consensus estimates of $0.22 by ($0.07). Lifevantage had a return on equity of 29.59% and a net margin of 3.74%.The business had revenue of $48.93 million for the quarter, compared to the consensus estimate of $54.40 million. Lifevantage has set its FY 2026 guidance at 0.600-0.800 EPS.

Lifevantage Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, March 16th. Investors of record on Monday, March 2nd will be issued a $0.045 dividend. This represents a $0.18 dividend on an annualized basis and a dividend yield of 3.7%. The ex-dividend date of this dividend is Monday, March 2nd. Lifevantage’s payout ratio is currently 30.00%.

Analyst Ratings Changes

A number of equities analysts have weighed in on the stock. Loop Capital set a $5.00 target price on shares of Lifevantage in a research note on Thursday, February 5th. Lake Street Capital restated a “buy” rating on shares of Lifevantage in a research report on Thursday, February 5th. Wall Street Zen lowered Lifevantage from a “buy” rating to a “hold” rating in a research report on Saturday, November 8th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Lifevantage in a research note on Monday, December 29th. One equities research analyst has rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Lifevantage currently has an average rating of “Moderate Buy” and a consensus target price of $5.00.

Institutional Trading of Lifevantage

Several institutional investors and hedge funds have recently made changes to their positions in LFVN. Police & Firemen s Retirement System of New Jersey bought a new position in shares of Lifevantage in the 2nd quarter worth $31,000. JPMorgan Chase & Co. boosted its holdings in Lifevantage by 870.2% during the second quarter. JPMorgan Chase & Co. now owns 5,016 shares of the company’s stock worth $66,000 after buying an additional 4,499 shares during the last quarter. Franklin Resources Inc. acquired a new position in shares of Lifevantage during the 4th quarter worth about $74,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in shares of Lifevantage in the 2nd quarter valued at about $76,000. Finally, Aristides Capital LLC acquired a new stake in shares of Lifevantage in the 4th quarter valued at approximately $76,000. Institutional investors own 35.32% of the company’s stock.

Lifevantage Company Profile

LifeVantage Corporation is a publicly traded company that develops, markets and distributes nutritional supplements, skincare products and weight-management solutions through a direct-selling business model. The company’s flagship offering, Protandim®, is formulated to activate the Nrf2 pathway, which is associated with cellular defense processes. LifeVantage also markets the PhysIQ® line for metabolism and body composition support and the TrueScience® skincare regimen, targeting a range of health and wellness needs.

Founded in 1999 and headquartered in Sandy, Utah, LifeVantage combines research in nutrigenomics with a network of independent distributors to bring its products to market.